TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Next Previous
Trial Profile

TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2015 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top